Table 2.

Management and Outcomes of S. aureus bacteremia by Day 4 Outcome

Characteristic	Resolving SAB (n=149)	Persistent SAB (n=47)	P value
Management
Received ID consult a	77 (52%)	34 (72%)	0.02
Time to receive consultation (days) b, c	2 (1,4)	1 (1,2)	0.05
Consult received prior to day 4 a, b	67 (87%)	29 (85%)	0.77
Time to receipt of effective Anti-SA therapy (days) c	0 (0, 1)	0 (0, 1)	0.16
Empiric Antibiotic therapy a
Vancomycin	122 (82%)	33 (70%)	0.10
Other anti-Staphylococcal	27 (18%)f	14 (30%)g	0.10
Hardware Removed a, d	34 (85%)	9 (90%)	1.00
Time to Hardware removal (days) c, d	2 (1, 3.75)	4 (2.5, 5)	0.06
Outcomes
30-day mortality a	7 (5%)	13 (28%)	<0.0001
30-day recurrence a, e	8 (6%)	1 (3%)	1.00
Length of hospital stay (days)c, e	10 (6, 17)	16.5 (10.8,25)	0.01

Abbreviations: ID, Infectious diseases; SA, S. aureus; MRSA, Methicillin-resistant S. aureus; MSSA, Methicillin-susceptible S. aureus;

^aChi- squared test;

^bOf those who received ID consult;

^cmedian (IQR) reported, Wilcoxon rank sum test;

^dOf those with infected hardware (n=40, n=10);

^eCalculated from surviving patients only;

^flinezolid, clindamycin, trimethoprim/sulfamethoxazole, daptomycin, ceftriaxone, oxacillin, cefazolin, other;

^gclindaymycin, linezolid, daptomycin, ceftriaxone, cefazolin